Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study

AP Kater, JF Seymour, P Hillmen, B Eichhorst, Ton Langerak, C Owen, M Verdugo, J Wu, EA Punnoose, YW Jiang, Johnny Wang, M Boyer, K Humphrey, M Mobasher, TJ Kipps

Research output: Contribution to journalArticleAcademicpeer-review

246 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)269-+
JournalJournal of Clinical Oncology
Issue number4
Publication statusPublished - 2019

Research programs

  • EMC MM-02-72-01

Cite this